Krogh-Jensen M, D'Amore F, Jensen M K, Christensen B E, Thorling K, Pedersen M, Johansen P, Boesen A M, Andersen E
Department of Haematology, Aalborg Hospital, Denmark.
Leuk Lymphoma. 1995 Oct;19(3-4):223-33. doi: 10.3109/10428199509107892.
It has been claimed that Primary Central Nervous System Lymphomas (PCNSL), a rare neoplasm accounting for only a small fraction of malignant brain tumors and extranodal non-Hodgkin lymphomas (NHL), occur with increasing frequency in immunologically normal as well as in immunocompromised individuals. In an attempt to characterize the clinicopathological features, outcome and prognostic factors of PCNSL we here report our experience in a large unselected series of patients from a well-defined region. In addition, we present data on trends in incidence of PCNSL and primary malignant brain tumors in a well-defined geographical area. In a Danish population-based NHL registry (LYFO) representing a population of 2.7 million all new cases of NHL were registered during the approximate 11-year period from 1st January 1983 to 31st May 1994. Incidence data of primary malignant tumors of the brain and central nervous system in western Denmark for the period 1971-1990 have been obtained from the Danish Cancer Registry. During the approximate 11-year period 3124 new cases of NHL were registered. Of these, 1152 (37%) were extranodal and 48 were non-AIDS related PCNSL accounting for 4.2% of extranodal NHL and 1.5% of all NHL, respectively. The average annual incidence rate of non-AIDS related PCNSL during the period was 1.56 cases per million population (age range: 15-85 yrs, median: 62 yrs, M/F ratio: 1). In a 23-year period there was no trend towards an increasing incidence of non-AIDS related PCNSL in a well-defined population. PCNSL accounted for 1.7% of all primary malignant brain tumors. Incidence of primary malignant brain tumors was stable, except for age ranges over 70 years. However, diagnostic artifacts might be responsible for this apparent increase. Histologically, 85% were high grade. Using the Kiel classification centroblastic diffuse (60%) and immunoblastic lymphoma (13%) were the most common subtypes. Forty-three patients had B-cell lymphoma and no T-cell lymphoma was detected. Forty-seven cases were diagnosed pre mortem. Treatment included surgical resection (26 patients), whole brain irradiation (WBRT) (43 patients) and chemotherapy (28 patients). Median survival for those receiving either WBRT or WBRT and chemotherapy was 8 months and 20 months, respectively (p = 0.78). Overall survival was 53%, 38% and 26% at 1, 2 and 5 years. Cox-regression analysis identified only one factor having independent impact on survival in PCNSL: performances score > or = 2 (p < 0.001, RR = 5.8).
有人声称,原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的肿瘤,仅占恶性脑肿瘤和结外非霍奇金淋巴瘤(NHL)的一小部分,在免疫功能正常以及免疫功能低下的个体中发病率都在增加。为了描述PCNSL的临床病理特征、结局和预后因素,我们在此报告来自一个明确地区的大量未经选择的患者系列的经验。此外,我们还展示了一个明确地理区域内PCNSL和原发性恶性脑肿瘤发病率趋势的数据。在一个代表270万人口的丹麦基于人群的NHL登记处(LYFO),从1983年1月1日至1994年5月31日的大约11年期间登记了所有新的NHL病例。1971 - 1990年丹麦西部脑和中枢神经系统原发性恶性肿瘤的发病率数据已从丹麦癌症登记处获得。在大约11年期间,登记了3124例新的NHL病例。其中,1152例(37%)为结外病例,48例为非艾滋病相关的PCNSL,分别占结外NHL的4.2%和所有NHL的1.5%。该期间非艾滋病相关PCNSL的年均发病率为每百万人口1.56例(年龄范围:15 - 85岁,中位数:62岁,男女比例:1)。在23年期间,在一个明确的人群中,非艾滋病相关PCNSL的发病率没有增加的趋势。PCNSL占所有原发性恶性脑肿瘤的1.7%。原发性恶性脑肿瘤的发病率是稳定的,70岁以上年龄组除外。然而,诊断假象可能是这种明显增加的原因。组织学上,85%为高级别。采用 Kiel分类,中心母细胞弥漫型(60%)和免疫母细胞淋巴瘤(13%)是最常见的亚型。43例为B细胞淋巴瘤,未检测到T细胞淋巴瘤。47例在死前被诊断。治疗包括手术切除(26例患者)、全脑照射(WBRT)(43例患者)和化疗(28例患者)。接受WBRT或WBRT联合化疗的患者的中位生存期分别为8个月和20个月(p = 0.78)。1年、2年和5年的总生存率分别为53%、38%和26%。Cox回归分析确定在PCNSL中对生存有独立影响的因素只有一个:体能状态评分≥2(p < 0.001,RR = 5.8)。